Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer
Not Applicable
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000017718
- Lead Sponsor
- Department of Surgical Oncology, Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Other active concomitant malignancies; other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine; pregnant women; no informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method R0 resection rate
- Secondary Outcome Measures
Name Time Method Completion rate of chemotherapy, Relative Dose Intensity (DOI), Frequency and severity of adverse event, efficacy of chemotherapy, disease free survival, overall survival and complication of surgery